Navigation Links
Ascension Orthopedics Launches the TITAN(TM) Humeral Resurfacing Device World Wide
Date:1/30/2008

AUSTIN, Texas, Jan. 30 /PRNewswire/ -- Ascension Orthopedics, Inc. announced today that the TITAN(TM) humeral resurfacing device is now available to help people who suffer from debilitating shoulder disorders.

Ascension received FDA approval for the TITAN(TM) in October 2006 and recently completed a successful beta site launch in the U.S. The TITAN(TM) is now available worldwide.

The Ascension TITAN(TM) system provides a stable, bone conserving option for humeral head arthroplasty. The TITAN(TM) has advanced the concept of humeral resurfacing by offering a unique four finned stem design that allows for greater purchase in the bone and enhanced stability.

"The TITAN(TM) humeral resurfacing implant expands Ascension's focus on Upper Extremity. The TITAN(TM) resurfacing device provides a less invasive option for the shoulder with a stable, anatomic implant. Humeral head resurfacing is a rapidly growing segment of the shoulder market. We are excited to expand our product offering in the extremity market," said Andy Miclot, President/CEO.

Ascension Orthopedics is dedicated to the research and development of orthopedic implants for the hand, upper extremity, and foot. Ascension's mission is to help surgeons treat patients suffering from pain and dysfunction by applying state of the art biomaterials, design, and manufacturing technology. For further information, please visit http://www.ascensionortho.com/.

FOR FURTHER INFORMATION CONTACT:

Andrew J. Miclot

President / CEO

Ascension Orthopedics, Inc.

512-836-5001


'/>"/>
SOURCE Ascension Orthopedics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Ascension Orthopedics Closes $21 Million Financing and Recruits an Orthopedics Industry Veteran as CEO
2. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
3. UPMC Health Plan Launches New Personal Health Record
4. HealthInsuranceFinders.com Launches Video Contest for Young Directors
5. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
6. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
7. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
8. Mannatech Launches Phase One of New Sales and Training Tools
9. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
10. Actavis Launches Carvedilol Tablets in the U.S.
11. MedQuist Re-launches New, Improved Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
(Date:4/17/2014)... led by Cesar A. Arias, M.D., Ph.D., at The ... has identified a new superbug that caused a bloodstream ... the April 17 issue of The New England ... part of a class of highly-resistant bacteria known as ... a major cause of hospital and community-associated infections. The ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... Cystitis Epidemiology (RICE) study estimates prevalence of 3 to ... 13 Three to eight million women in the ... newly released prevalence number, presented at the 2009 American ... to 6 percent of all U.S. women. This ...
... 13 Cyberonics, Inc. (Nasdaq: CYBX ) today ... fourth quarter and fiscal year ended April 24, 2009 on ... company will conduct a conference call to discuss those results ... Fourth Quarter and FY2009 Results Conference Call Instructions ...
... Fixed-dose combination offers a convenient option that may ... pressure goals while decreasing patient pill burden(1)PARSIPPANY, N.J., ... that the United States Food and Drug Administration ... and olmesartan medoxomil) as initial or ,first-line, therapy ...
... Surgical Information Systems (SIS) successfully completed the ... the Healthcare Enterprise (IHE) Connectathon, and participated ... Society (HIMSS) Interoperability Showcase in Chicago.(Logo: ... )The Connectathon is the healthcare IT industry,s ...
... Watts Enables Physicians to Melt and Remove Larger Areas ... May 13 Cynosure, Inc. ... manufacturer of a broad array of light-based aesthetic treatment ... the latest and most powerful advance in the company,s ...
... experts say , , WEDNESDAY, May 13 (HealthDay News) -- ... normal-weight co-workers, says a U.S. study. , Researchers surveyed ... effectiveness and impairment of daily activities. The results showed ... diabetes lost 11 percent to 15 percent of work ...
Cached Medicine News:Health News:Prevalence of Interstitial Cystitis in U.S. Much Larger Than Previously Believed 2Health News:Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Financial Results 2Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 2Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 3Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 4Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 5Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 6Health News:SIS Completes IHE Connectathon, Participates in HIMSS Interoperability Showcase 2Health News:Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing 2Health News:Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing 3Health News:Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing 4Health News:Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing 5Health News:Productivity Takes a Hit From Obesity, Diabetes 2
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... IOMI ) today announced that Stanley C. Erck, the ... Acumen BioFin,Rodman & Renshaw 9th Annual Healthcare Conference in ... will begin at 9:10 a.m. Eastern,Time in the Kennedy ... Mr. Erck,s presentation will focus on Iomai,s portfolio of ...
... Exelixis, Inc. (Nasdaq:,EXEL) today presented data from ... with albuminuria due to diabetic nephropathy. XL784 is ... enzymes that may,play a role in the pathogenesis ... presented during a poster session (Abstract/Poster PO1030) at,the ...
Cached Medicine Technology:Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 3Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 4
... developed over Guidants 20-year history, the VOYAGER ... for successful treatment outcomes. It combines a ... a lower profile shaft,more flexible markers, and ... cross tight and tortuous anatomy with even ...
... technology developed over Guidants 20-year history, the ... foundation for successful treatment outcomes. It combines ... with a lower profile shaft,more flexible markers, ... can cross tight and tortuous anatomy with ...
Test for AFP...
Enzyme Immunoassay for the Quantitative Measurement of Ovarian Cancer Antigen CA-125 in Human Serum...
Medicine Products: